Author: FibroBiologics, Inc.

Posted Date:

May 11, 2026

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus

FibroBiologics, Inc.

May 11, 2026
FibroBiologics CEO Issues Letter to Shareholders

FibroBiologics, Inc.

May 5, 2026
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring

FibroBiologics, Inc.

May 4, 2026
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

FibroBiologics, Inc.

May 4, 2026
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update

FibroBiologics, Inc.

April 30, 2026
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026

FibroBiologics, Inc.

April 30, 2026
FibroBiologics Compliant with All Nasdaq Listing Requirements

FibroBiologics, Inc.

April 20, 2026
FibroBiologics Announces Closing of $3 Million Public Offering

FibroBiologics, Inc.

April 2, 2026
FibroBiologics Announces Pricing of $3 Million Public Offering

FibroBiologics, Inc.

March 31, 2026
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

FibroBiologics, Inc.

March 31, 2026